SGD Pharma speeds up time to market with industry first Ready-to-Use Nest & Tub packaging solution for molded glass vials

Increased demand for parenteral drugs generated by the Covid-19 pandemic has resulted in additional pressures being placed on biopharmaceutical companies to accelerate their time-to-market. This new RTU primary and secondary packaging combination from SGD Pharma offers biopharmaceutical producers the flexibility they need to deliver innovative medicines to patients significantly faster.

SGD Pharma was the first molded glass manufacturer to offer RTU vials at an industrial scale for injectable drugs in 2019, and its partnership with Stevanato Group has enabled the company to be the first to market with 20ml EasyLyo molded glass Type I vials in EZ-fill® Nest & Tub. RTU Type I molded glass vials are delivered pre-sterilized in Nest & Tubs ready for automated fill and finish, skipping up-front washing and depyrogenation steps in an aseptic environment and allowing pharma companies to focus on core business activities to expedite product launches.

Nest & Tub is a secondary packaging solution required for combi-lines used for fill and finish. It is largely adopted by contract manufacturing organizations (CMOs) and contract development manufacturing organizations (CDMOs) for processing a variety of primary packaging containers including vials, syringes, and cartridges for optimal manufacturing flexibility. The Nest & Tub solution avoids glass-to-glass contact, protecting the sterility and the integrity of each vial. With the introduction of SGD Pharma’s RTU molded glass packaging solution in EZ-fill® Nest & Tub, drug manufacturers can accelerate their time-to-market for small to medium batches with minimal filling line changes.

SGD Pharma identified 20ml EasyLyo molded glass Type I vials, part of the Sterinity platform, as a priority for development in Nest & Tub packaging due to the specific needs of biopharmaceutical companies to protect the safety of lyophilized drugs. EasyLyo’s optimized heel radius reduces the risk of costly breakages in the freeze-drier and by removing the vials’ base mold marks, manufacturers can achieve uniform cakes through maximized heat transfer. The uniform wall thickness of EasyLyo vials improves their cosmetic appearance, providing better inspectability compared with standard molded glass.

Alexander Bautista, Product Manager Sterinity Platform, confirms: “Our new 20ml EasyLyo molded glass Type I RTU vial in Nest & Tub is an optimal packaging option for biologics and innovative treatments that require glass vials with large volumes for parenteral use. The chemical and mechanical resistance of our Type I molded glass vials ensure reduced risk of delamination and breakages; in particular for drugs manufactured via lyophilization. This meets the needs of innovative drug manufacturers through all the stages of drug development, especially the early phases and the transition from clinical to commercial.”

With the same external dimension as 20R tubular vials, adopting 20ml EasyLyo molded glass Type I vials will only require minor changes on the filling line and allow the same freeze-drier shelf configuration. This makes it simple for drug manufacturers to adopt a multi-source approach or add molded glass vials to their primary packaging portfolio. Customers looking to add Type I molded glass vials as an alternative packaging solution are advised to start stability testing to ensure supply chain continuity in the event of shortages.

Molded glass represents approximately 40% of the injectable vials market: its higher mechanical resistance reduces the risk of breakages during fill/finish and harsh processing conditions such as lyophilization, safeguarding valuable drug products and sensitive molecules, such as oncology therapies. Improved chemical performance minimizes extractables and particle contamination to meet United States Pharmacopoeia (USP) and USP guidelines.

The new 20ml EasyLyo molded Type I glass vials in Nest & Tub are in stock and available in both flint and amber glass. The Letter of Authorization (LOA) to the Drug Master Files (DMF) for our Ready-To-Use molded glass vials, pre-sterilized in the EZ-fill® platform of SG Ompi, will be available from early July.

See also

SGD Pharma launches industry first ready-to-use sterile 100 ml molded glass vials in SG EZ-fill packaging technology

Worldwide glass primary packaging supplier SGD Pharma has announced the introduction of its 100H ml Ready-to-Use (RTU) Type I molded glass vials for aseptic fill/finish of parenteral drug products. The addition of 100 ml molded glass vials to the Sterinity platform is pioneering, with SGD Pharma being the first global molded glass manufacturing company to offer this size of solution in the RTU market.

SGD Pharma upgrades its Chinese plant toward an automated and improved production

SGD Pharma's Zhanjiang (China) plant produces 1.2 million Type II & III flint molded glass vials daily for the parenteral market and for health care beauty products. With a surface of ​​85,000m2, the plant included a glass furnace, 6 production lines, an ISO 8 clean room of 2000m2, a resorting room and a customization workshop. In early 2018, SGD Pharma invested 7 million Euros to improve the automation and the production, including the rebuilding of the furnace, to make the plant an exemplary production center.

  • Jo Webb
  • Product Info
  • English
  • Created 18 Jun 2021
  • Modified 21 Mar 2022
  • Hits 348